An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Graphite Bio Announces Participation in Morgan Stanley 20th Annual Global Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Graphite Bio (Nasdaq: GRPH), a leader in gene editing, announced its participation in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Sept. 13, 2022, at 12:55 pm ET. The discussion will be broadcast live on the company’s website, with a replay available afterward. Graphite Bio is focused on developing innovative gene therapies utilizing its UltraHDR™ platform, which aims to enhance precision gene repair and potentially cure severe diseases by correcting genetic mutations.
Positive
Participation in a prestigious healthcare conference could enhance visibility and investor interest.
Showcases commitment to advancing gene editing technology through its UltraHDR™ platform.
Negative
None.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to cure serious diseases, today announced that members of the management team will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, Sept. 13, 2022, at 12:55 pm ET.
The fireside chat will be webcast live from Graphite Bio’s website at www.graphitebio.com in the Investors section. A replay of the webcast will be archived and available following the event.
About Graphite Bio
Graphite Bio is a clinical-stage, next-generation gene editing company driven to discover and develop cures for a wide range of serious and life-threatening diseases. The company is pioneering a precision gene editing approach that has the potential to transform human health by achieving one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s UltraHDR™ gene editing platform takes CRISPR beyond cutting and harnesses the power of high-efficiency precision DNA repair, also known as homology directed repair (HDR), to precisely correct genetic mutations, replace entire disease-causing genes with functional genes or insert new genes into predetermined, safe locations. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D.
